The client wanted to develop pricing and market access strategies for a biologic compound with a complex lifecycle plan as it approached Phase III clinical trials
Kasocio developed a multi-layered approach to inflexion robust and compelling pricing and access assumptions within a challenging project timeline.
Kasocio used a combination of pricing analogues, primary research with a mix of P&T-level Payer decision makers, and comparator cost-effectiveness analyses to develop baseline, upside, and downside pricing and market access estimates for the client’s strategic forecast.
Our work clarified price/volume tradeoff assumptions and identified a clear inflexion point at which pricing could result in significant access restriction.
We also provided strategic recommendations on how pricing for the lead indication could impact future indications and where rebate contracts, in the U.S., could mitigate future risks.
To download a PDF click here